- Available:In stock654
- Availability date:2020-07-30
- Dosage form:Liquid (Tube)
- In stock:654 Items
microlax® has a chemical and mechanical effect. sodium citrate displaces the bound water contained in feces. Due to the crystallizing sorbitol solution, the effect of sodium citrate on water displacement is enhanced. sodium lauryl sulfoacetate is a non-toxic moisturizing agent that does not cause irritation. It facilitates the penetration of the rectal solution into the feces. this process facilitates the liquefaction of feces and enables the patient with constipation to complete the act of defecation within a few minutes, usually 5-20 minutes. the process of displacing bound water by chemical and mechanical methods is called peptization. an increase in the amount of water due to peptization and liquefaction helps to soften feces and facilitates bowel movement.
Constipation (short-term use), as well as diseases requiring relief of bowel movements.
For bowel movements during diagnostic and therapeutic measures in the rectal area.
The drug is used rectally.
One dose of the drug should be used 5–20 minutes before the desired effect.
Adults and children over the age of 3 years should use the contents of 1 tube of microclysters with a tip (5 ml), introducing the entire length of the microclyster tip.
Newborns and children under the age of 3 years should use the contents of 1 tube of microclysters with a tip (5 ml) and introduce the tip of microclysters half the length (see the mark on the tip of the tube).
Instructions for use. Break off the seal on the tip of the tube. Press lightly on the tube so that a drop of the drug lubricates the tip of the tip of the microclyster to improve the administration process. Insert the tip of the microclyster over the entire length (children under 3 years - half the length) into the rectum.
Squeezing the tube, completely squeeze out its contents. Remove the tip while continuing to squeeze the tube.
Hypersensitivity to active substances or any of the excipients that make up the drug; intestinal obstruction; diagnosis of hereditary fructose intolerance (intolerance to a certain type of sugar).
The frequency of adverse reactions is determined as follows: very often - 1/10; often - from 1/100 to 1/10; infrequently - from 1/1000 to 1/100; rarely - from 1/10 000 to 1/1000; very rarely - 1/10 000; frequency is unknown - based on the available data, the frequency cannot be estimated.
On the part of the immune system: frequency is unknown - hypersensitivity reactions (eg urticaria).
From the gastrointestinal tract: the frequency is unknown - abdominal pain, slight burning in the anus, loose stools.
Sorbic acid can cause mucosal irritation.
If symptoms persist for a long time, you should consult a doctor and avoid long-term use of the drug.
If the content of the tube is used only partially, the remainder of the rectal solution must be disposed of.
Use during pregnancy and lactation. Studies involving pregnant women have not been conducted. Since the drug, if used in accordance with the recommendations, most likely has only a slight systemic absorption, no harmful effect on the health of the fetus / newborn when using the drug during pregnancy and lactation is expected.
It is not known whether sodium citrate, sodium lauryl sulfoacetate, and sorbitol pass into breast milk. During breastfeeding, the use of the drug is recommended after consulting a doctor and assessing the risk / benefit for the child.
Children. Used in children from birth.
The ability to influence the reaction rate when driving vehicles or other mechanisms. Unknown
Studies of the interaction of the drug microlax® with other drugs have not been conducted.
Since Microlax® contains sorbitol, it is not recommended to use it simultaneously with ion-exchange resins, which are used orally or rectally to treat hyperkalemia, because of the risk of developing intestinal necrosis.
At the moment, no cases of overdose have been reported.
At a temperature not exceeding 25 ° C. expiration date - 3 years.